Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study

BACKGROUND: Immunocheckpoint inhibitor(ICI) is a major breakthrough in tumor treatment. It can activate the patient’s own immune system and play an anti-tumor role, but not all patients can benefit from it. At present, there is still a lack of effective biomarkers to guide clinical application. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Fei, Meng, Qingju, Zhang, Lei, Chen, Jingli, Zhao, Liyan, Zhou, Zhiguo, Liu, Yibing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326931/
https://www.ncbi.nlm.nih.gov/pubmed/37420219
http://dx.doi.org/10.1186/s12957-023-03077-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326931/
https://www.ncbi.nlm.nih.gov/pubmed/37420219
http://dx.doi.org/10.1186/s12957-023-03077-8

Ejemplares similares